2. Academic Validation
  3. Targeted delivery and ROS-responsive release of Resolvin D1 by platelet chimeric liposome ameliorates myocardial ischemia-reperfusion injury

Targeted delivery and ROS-responsive release of Resolvin D1 by platelet chimeric liposome ameliorates myocardial ischemia-reperfusion injury

  • J Nanobiotechnology. 2022 Oct 20;20(1):454. doi: 10.1186/s12951-022-01652-x.
Xueyi Weng # 1 2,  Haipeng Tan # 1 2,  Zheyong Huang # 1 2,  Jing Chen 1 2,  Ning Zhang 1 2,  Qiaozi Wang 1 2,  Qiyu Li 1 2,  Jinfeng Gao 1 2,  Dili Sun 1 2,  Wusiman Yakufu 1 2,  Zhengmin Wang 1 2,  Weiyan Li 1 2,  Guangrui Zhu 1 2,  Zhiqing Pang 3,  Yanan Song 4 5,  Juying Qian 6 7,  Junbo Ge 1 2 8
Affiliations

Affiliations

  • 1 Department of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases , Fudan University, 180 Feng Lin Road, Shanghai, 200032, China.
  • 2 National Clinical Research Center for Interventional Medicine & Shanghai Clinical Research Center for Interventional Medicine, 180 Feng Lin Road, Shanghai, 200032, China.
  • 3 School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry of Education, Fudan University, 826 Zhangheng Road, Shanghai, 201203, China. zqpang@fudan.edu.cn.
  • 4 Department of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases , Fudan University, 180 Feng Lin Road, Shanghai, 200032, China. yanan.song@163.com.
  • 5 National Clinical Research Center for Interventional Medicine & Shanghai Clinical Research Center for Interventional Medicine, 180 Feng Lin Road, Shanghai, 200032, China. yanan.song@163.com.
  • 6 Department of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases , Fudan University, 180 Feng Lin Road, Shanghai, 200032, China. Qian.juying@zs-hospital.sh.cn.
  • 7 National Clinical Research Center for Interventional Medicine & Shanghai Clinical Research Center for Interventional Medicine, 180 Feng Lin Road, Shanghai, 200032, China. Qian.juying@zs-hospital.sh.cn.
  • 8 Institute of Biomedical Science, Fudan University, 180 Feng Lin Road, Shanghai, 200032, China.
  • # Contributed equally.
PMID: 36266658 DOI: 10.1186/s12951-022-01652-x
Abstract

Resolvin D1 (RvD1) has been shown to provide effective protection against ischemia-reperfusion injury in multiple vital organs such as the heart, brain, kidney. However, the clinical translational potential of systemic administration of RvD1 in the treatment of ischemia-reperfusion injury is greatly limited due to biological instability and lack of targeting ability. Combining the natural inflammatory response and Reactive Oxygen Species (ROS) overproduction after reperfusion injury, we developed a platelet-bionic, ROS-responsive RvD1 delivery platform. The resulting formulation enables targeted delivery of RvD1 to the injury site by hijacking circulating chemotactic monocytes, while achieving locally controlled release. In a mouse model of myocardial ischemia repefusuin (MI/R) injury, intravenous injection of our formula resulted in the enrichment of RvD1 in the injured area, which in turn promotes clearance of dead cells, production of specialized proresolving mediators (SPMs), and angiogenesis during injury repair, effectively improving cardiac function. This delivery system integrates drug bio-protection, targeted delivery and controlled release, which endow it with great clinical translational value.

Keywords

Biomimetic; Macrophages; Monocytes; Myocardial ischemia–reperfusion injury; Platelets; ROS responsive.

Figures
Products